<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00841776</url>
  </required_header>
  <id_info>
    <org_study_id>DTG0703</org_study_id>
    <nct_id>NCT00841776</nct_id>
  </id_info>
  <brief_title>Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatment of Facial Acne</brief_title>
  <official_title>Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatment of Moderate to Moderately Severe Facial Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stiefel, a GSK Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the development of microbial resistance when using
      one of two topical acne therapies for the treatment of facial acne vulgaris.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To investigate the development of microbial resistance when using one of two topical acne
      therapies for the treatment of moderate to moderately severe facial acne vulgaris. Clinical
      efficacy and tolerability will be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Change in Total Propionibacterium Acne (P.Acne) Counts</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, &amp; 16</time_frame>
    <description>Median change in total colony forming units of propionibacterium acne (P.acne) will be counted.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Change in Clindamycin Resistant P. Acne.</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, 16</time_frame>
    <description>Median change in total colony forming units of clindamycin resistant p. acne.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change in Erythromycin-resistant P. Acne Counts</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, and 16</time_frame>
    <description>Total colony forming units of erythromycin-resistant p. acnes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change in Total Acne Lesions</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, and 16</time_frame>
    <description>Median Change in Total Acne Lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change in Inflammatory Acne Lesion Counts</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, and 16</time_frame>
    <description>Median Change in Inflammatory Acne Lesion Counts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change in Noninflammaotry Acne Counts</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, and 16</time_frame>
    <description>Median Change in Noninflammaotry Acne Counts</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Acne</condition>
  <arm_group>
    <arm_group_label>Duac gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clindamycin and benzoyl peroxide gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ziana gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clindamycin and tretinoin gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duac</intervention_name>
    <description>Clindamycon and benzoyl peroxide topical gel once a day for 12 weeks</description>
    <arm_group_label>Duac gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ziana gel</intervention_name>
    <description>Clindamycin and tretinoin gel once a day for 12 weeks.</description>
    <arm_group_label>Ziana gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatient at least 12 years of age. Female subjects of childbearing potential must
             have a negative urine pregnancy test result at baseline and practice a reliable method
             of contraception throughout the study.

          -  Mild to moderate facial acne vulgaris

          -  Able to understand the requirements of the study and sign informed consent/HIPAA
             authorization forms. Subjects under the legal age of consent in the state where the
             study is conducted must also have the written, informed consent of a parent or legal
             guardian.

        Exclusion Criteria:

          -  Female subjects who are pregnant (positive urine pregnancy test), breast feeding or
             who are of childbearing potential and not practicing a reliable method of birth
             control

          -  Allergy or sensitivity to any component of the test medication

          -  Known hypersensitivity to to any component of the investigational formulations

          -  Known history of enteritis (regional enteritis, ulcerative colitis, pseudomembranous
             colitis, or antibiotic-associated colitis

          -  Beards or sideburns

          -  Skin disease/disorder that might interfere with the diagnosis or evaluation of acne
             vulgaris

          -  Evidence of recent alcohol or drug abuse

          -  Participation in an investigational drug study within 30 days of the baseline visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dermatology Specialists, PSC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin We Care Dermatology</name>
      <address>
        <city>Mason</city>
        <state>Ohio</state>
        <zip>45040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Jackson JM, Fu JJ, Almekinder JL. A randomized, investigator-blinded trial to assess the antimicrobial efficacy of a benzoyl peroxide 5%/ clindamycin phosphate 1% gel compared with a clindamycin phosphate 1.2%/tretinoin 0.025% gel in the topical treatment of acne vulgaris. J Drugs Dermatol. 2010 Feb;9(2):131-6.</citation>
    <PMID>20214175</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2009</study_first_submitted>
  <study_first_submitted_qc>February 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2009</study_first_posted>
  <results_first_submitted>April 7, 2010</results_first_submitted>
  <results_first_submitted_qc>June 29, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 23, 2010</results_first_posted>
  <last_update_submitted>May 24, 2017</last_update_submitted>
  <last_update_submitted_qc>May 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acne Vulgaris</keyword>
  <keyword>Acne</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Infective Agents</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Benzoyl Peroxide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Clinical research center</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Duac</title>
          <description>Clindamycin and benzoyl peroxide topical gel</description>
        </group>
        <group group_id="P2">
          <title>Ziana</title>
          <description>Clindamycin and topical tretinoin gel</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Duac</title>
          <description>Clindamycin and benzoyl peroxide topical gel</description>
        </group>
        <group group_id="B2">
          <title>Ziana</title>
          <description>Clindamycin and topical tretinoin gel</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.6" spread="6.9"/>
                    <measurement group_id="B2" value="16.2" spread="4.9"/>
                    <measurement group_id="B3" value="16.9" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Acne Lesion Counts</title>
          <description>P. acne Lesion Counts</description>
          <units>Acne Lesion Counts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Inflammatory Lesion Counts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.74" spread="10.61"/>
                    <measurement group_id="B2" value="22.78" spread="7.07"/>
                    <measurement group_id="B3" value="23.76" spread="8.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Noninflammatory Lesion Counts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.30" spread="20.38"/>
                    <measurement group_id="B2" value="35.11" spread="15.40"/>
                    <measurement group_id="B3" value="34.70" spread="17.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Lesion Counts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.04" spread="23.68"/>
                    <measurement group_id="B2" value="57.89" spread="19.99"/>
                    <measurement group_id="B3" value="58.46" spread="21.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinidamycin-resistant propionibacterium acne (P.acne) counts</title>
          <description>Clinidamycin-resistant Colony Forming Unit Propionibacterium acne counts</description>
          <units>Clinidamycin-resistant p. acne counts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.29" spread="1.34"/>
                    <measurement group_id="B2" value="2.02" spread="1.21"/>
                    <measurement group_id="B3" value="2.16" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Erythromycin-resistant lesion count</title>
          <description>Erythromycin-resistant Colony forming Unit lesion count</description>
          <units>Erythromycin-resistant lesion count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.29" spread="1.37"/>
                    <measurement group_id="B2" value="1.92" spread="1.11"/>
                    <measurement group_id="B3" value="2.10" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Propionibacterium acne counts</title>
          <description>Mean colony forming unit P. acne counts</description>
          <units>P. acne counts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.63" spread="1.12"/>
                    <measurement group_id="B2" value="4.74" spread="0.58"/>
                    <measurement group_id="B3" value="4.69" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Change in Total Propionibacterium Acne (P.Acne) Counts</title>
        <description>Median change in total colony forming units of propionibacterium acne (P.acne) will be counted.</description>
        <time_frame>Baseline, Weeks 2, 4, 8, 12, &amp; 16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Duac</title>
            <description>Clindamycin and benzoyl peroxide topical gel</description>
          </group>
          <group group_id="O2">
            <title>Ziana</title>
            <description>Clindamycin and topical tretinoin gel</description>
          </group>
        </group_list>
        <measure>
          <title>Median Change in Total Propionibacterium Acne (P.Acne) Counts</title>
          <description>Median change in total colony forming units of propionibacterium acne (P.acne) will be counted.</description>
          <units>P. acne counts</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline to Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.26" spread="1.44" lower_limit="-2.42" upper_limit="-0.4"/>
                    <measurement group_id="O2" value="-0.08" spread="0.82" lower_limit="-0.67" upper_limit="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.58" spread="1.49" lower_limit="-2.27" upper_limit="-0.61"/>
                    <measurement group_id="O2" value="-0.67" spread="1.18" lower_limit="-1.31" upper_limit="-0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.65" spread="1.50" lower_limit="-2.43" upper_limit="-0.68"/>
                    <measurement group_id="O2" value="-0.32" spread="1.04" lower_limit="-0.84" upper_limit="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.82" spread="1.60" lower_limit="-3.62" upper_limit="-1.0"/>
                    <measurement group_id="O2" value="-0.59" spread="0.99" lower_limit="-1.07" upper_limit="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.48" spread="1.77" lower_limit="-3.08" upper_limit="-0.82"/>
                    <measurement group_id="O2" value="-0.57" spread="0.83" lower_limit="-1.18" upper_limit="-0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change in Clindamycin Resistant P. Acne.</title>
        <description>Median change in total colony forming units of clindamycin resistant p. acne.</description>
        <time_frame>Baseline, Weeks 2, 4, 8, 12, 16</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Duac</title>
            <description>Clindamycin and benzoyl peroxide topical gel</description>
          </group>
          <group group_id="O2">
            <title>Ziana</title>
            <description>Clindamycin and topical tretinoin gel</description>
          </group>
        </group_list>
        <measure>
          <title>Median Change in Clindamycin Resistant P. Acne.</title>
          <description>Median change in total colony forming units of clindamycin resistant p. acne.</description>
          <population>ITT</population>
          <units>Clindamycin- resistant P. acne counts</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline to Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" lower_limit="-1.74" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-1.43" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="-0.51" upper_limit="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" lower_limit="-1.95" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="-0.10" upper_limit="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" lower_limit="-1.53" upper_limit="0"/>
                    <measurement group_id="O2" value="0.39" lower_limit="0" upper_limit="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" lower_limit="-1.84" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="-0.03" upper_limit="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change in Erythromycin-resistant P. Acne Counts</title>
        <description>Total colony forming units of erythromycin-resistant p. acnes.</description>
        <time_frame>Baseline, Weeks 2, 4, 8, 12, and 16</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Duac</title>
            <description>Clindamycin and benzoyl peroxide topical gel</description>
          </group>
          <group group_id="O2">
            <title>Ziana</title>
            <description>Clindamycin and topical tretinoin gel</description>
          </group>
        </group_list>
        <measure>
          <title>Median Change in Erythromycin-resistant P. Acne Counts</title>
          <description>Total colony forming units of erythromycin-resistant p. acnes.</description>
          <population>ITT</population>
          <units>Erythromycin-resistant P. acne counts</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline to Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" lower_limit="-1.67" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" lower_limit="-1.51" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" lower_limit="-2.26" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.91" lower_limit="-1.68" upper_limit="0"/>
                    <measurement group_id="O2" value="0.15" lower_limit="0" upper_limit="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-1.81" upper_limit="0"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0" upper_limit="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change in Total Acne Lesions</title>
        <description>Median Change in Total Acne Lesions</description>
        <time_frame>Baseline, Weeks 2, 4, 8, 12, and 16</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Duac</title>
            <description>Clindamycin and benzoyl peroxide topical gel</description>
          </group>
          <group group_id="O2">
            <title>Ziana</title>
            <description>Clindamycin and topical tretinoin gel</description>
          </group>
        </group_list>
        <measure>
          <title>Median Change in Total Acne Lesions</title>
          <description>Median Change in Total Acne Lesions</description>
          <population>ITT</population>
          <units>Total Acne Lesion Counts</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline to Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14" lower_limit="-22" upper_limit="-4"/>
                    <measurement group_id="O2" value="-13" lower_limit="-23" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22" lower_limit="-30" upper_limit="-16"/>
                    <measurement group_id="O2" value="-14" lower_limit="-24" upper_limit="-2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27" lower_limit="-38" upper_limit="-9"/>
                    <measurement group_id="O2" value="-19" lower_limit="-36" upper_limit="-5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.5" lower_limit="-36" upper_limit="-15"/>
                    <measurement group_id="O2" value="-23.5" lower_limit="-34" upper_limit="-11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33" lower_limit="-35" upper_limit="-22"/>
                    <measurement group_id="O2" value="-30" lower_limit="-41.5" upper_limit="-17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change in Inflammatory Acne Lesion Counts</title>
        <description>Median Change in Inflammatory Acne Lesion Counts</description>
        <time_frame>Baseline, Weeks 2, 4, 8, 12, and 16</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Duac</title>
            <description>Clindamycin and benzoyl peroxide topical gel</description>
          </group>
          <group group_id="O2">
            <title>Ziana</title>
            <description>Clindamycin and topical tretinoin gel</description>
          </group>
        </group_list>
        <measure>
          <title>Median Change in Inflammatory Acne Lesion Counts</title>
          <description>Median Change in Inflammatory Acne Lesion Counts</description>
          <population>ITT</population>
          <units>Lesion Counts</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline to Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7" lower_limit="-13" upper_limit="-1"/>
                    <measurement group_id="O2" value="-7" lower_limit="-15" upper_limit="-4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12" lower_limit="-18" upper_limit="-3"/>
                    <measurement group_id="O2" value="-7" lower_limit="-15" upper_limit="-1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11" lower_limit="-22" upper_limit="-6"/>
                    <measurement group_id="O2" value="-7" lower_limit="-16" upper_limit="-2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.5" lower_limit="-19" upper_limit="-7"/>
                    <measurement group_id="O2" value="-10.5" lower_limit="-17" upper_limit="-5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14" lower_limit="-20" upper_limit="-6"/>
                    <measurement group_id="O2" value="-14" lower_limit="-19" upper_limit="-8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change in Noninflammaotry Acne Counts</title>
        <description>Median Change in Noninflammaotry Acne Counts</description>
        <time_frame>Baseline, Weeks 2, 4, 8, 12, and 16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Duac</title>
            <description>Clindamycin and benzoyl peroxide topical gel</description>
          </group>
          <group group_id="O2">
            <title>Ziana</title>
            <description>Clindamycin and topical tretinoin gel</description>
          </group>
        </group_list>
        <measure>
          <title>Median Change in Noninflammaotry Acne Counts</title>
          <description>Median Change in Noninflammaotry Acne Counts</description>
          <units>Noninflammatory lesion counts</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline to Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6" lower_limit="-10" upper_limit="1"/>
                    <measurement group_id="O2" value="-6" lower_limit="-9" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10" lower_limit="-23" upper_limit="-3"/>
                    <measurement group_id="O2" value="-8" lower_limit="-18" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13" lower_limit="-17" upper_limit="-5"/>
                    <measurement group_id="O2" value="-12" lower_limit="-22" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9" lower_limit="-25" upper_limit="-4"/>
                    <measurement group_id="O2" value="-13.5" lower_limit="-18" upper_limit="-2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11" lower_limit="-20" upper_limit="-3"/>
                    <measurement group_id="O2" value="-16.5" lower_limit="-23" upper_limit="-7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Duac</title>
          <description>Clindamycin and benzoyl peroxide topical gel</description>
        </group>
        <group group_id="E2">
          <title>Ziana</title>
          <description>Clindamycin and topical tretinoin gel</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinus Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Gonorrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Head Cold</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Oral Thrush</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Attention Deficit Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Oily skin on face</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Skin surgery</sub_title>
                <description>Surgery performed while on study</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

